Biogen First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Biogen Inc. (NASDAQ:BIIB) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Guggenheim Adjusts Price Target on Biogen to $255 From $275
Biogen (BIIB) has an average outperform rating and a price target range of $200 to $350, according to analysts polled by Capital IQ. Price: 207.25, Change: +4.79, Percent Change: +2.36
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Here's What Analysts Are Forecasting For Biogen Inc. (NASDAQ:BIIB) After Its First-Quarter Results
It's been a good week for Biogen Inc. (NASDAQ:BIIB) shareholders, because the company has just released its latest first-quarter results, and the shares gained 6.3% to US$202. Biogen reported US
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)
Buy Rating Justified: Biogen's Promising Drug Launches and Strategic Growth Initiatives
Biogen's Financial Upswing: Strong Q1 Performance and Market Penetration Justify Buy Rating
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates From VRTX
Biogen Is Maintained at Equal-Weight by Barclays
Biogen Is Maintained at Equal-Weight by Barclays
Barclays: Maintaining the Biogen (BIIB.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $215.00 to $200.00.
Barclays: Maintaining the Biogen (BIIB.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $215.00 to $200.00.
Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $200
Barclays analyst Carter Gould maintains Biogen with a Equal-Weight and lowers the price target from $215 to $200.
Shareholders 30% Loss in Biogen (NASDAQ:BIIB) Partly Attributable to the Company's Decline in Earnings Over Past Year
These Analysts Revise Their Forecasts On Biogen After Q1 Results
Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its first quarter on Wednesday.Biogen reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The compa
Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Rosenblatt
Biogen Is Maintained at Buy by HC Wainwright & Co.
Biogen Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright Adjusts Biogen's Price Target to $300 From $325
HC Wainwright Adjusts Biogen's Price Target to $300 From $325.
Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB)
For Beaten-Down Maker of Alzheimer's Drug, Good Enough Will Do -- Heard on the Street -- WSJ
By David Wainer At first glance, Biogen didn't have a particularly exciting quarter. Sales dropped yet again to $2.29 billion, missing Wall Street estimates. The company's multiple sclerosis franchi
Wedbush Adjusts Price Target on Biogen to $215 From $213
Wedbush Adjusts Price Target on Biogen to $215 From $213.
No Data